209 related articles for article (PubMed ID: 28994212)
1. High frequency of brain metastases after adjuvant therapy for high-risk melanoma.
Samlowski WE; Moon J; Witter M; Atkins MB; Kirkwood JM; Othus M; Ribas A; Sondak VK; Flaherty LE
Cancer Med; 2017 Nov; 6(11):2576-2585. PubMed ID: 28994212
[TBL] [Abstract][Full Text] [Related]
2. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
Flaherty LE; Othus M; Atkins MB; Tuthill RJ; Thompson JA; Vetto JT; Haluska FG; Pappo AS; Sosman JA; Redman BG; Moon J; Ribas A; Kirkwood JM; Sondak VK
J Clin Oncol; 2014 Nov; 32(33):3771-8. PubMed ID: 25332243
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.
Kim KB; Legha SS; Gonzalez R; Anderson CM; Johnson MM; Liu P; Papadopoulos NE; Eton O; Plager C; Buzaid AC; Prieto VG; Hwu WJ; Frost AM; Alvarado G; Hwu P; Ross MI; Gershenwald JE; Lee JE; Mansfield PF; Benjamin RS; Bedikian AY
Melanoma Res; 2009 Feb; 19(1):42-9. PubMed ID: 19430405
[TBL] [Abstract][Full Text] [Related]
4. Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
Gibney GT; Atkins MB
J Clin Oncol; 2015 Jun; 33(17):1873-7. PubMed ID: 25964248
[TBL] [Abstract][Full Text] [Related]
5. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
[TBL] [Abstract][Full Text] [Related]
6. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
[TBL] [Abstract][Full Text] [Related]
7. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.
Atkins MB; Hsu J; Lee S; Cohen GI; Flaherty LE; Sosman JA; Sondak VK; Kirkwood JM;
J Clin Oncol; 2008 Dec; 26(35):5748-54. PubMed ID: 19001327
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
Hess V; Herrmann R; Veelken H; Schwabe M
Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
[TBL] [Abstract][Full Text] [Related]
9. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
[TBL] [Abstract][Full Text] [Related]
10. DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma.
Buzaid AC; Ali-Osman F; Akande N; Grimm EA; Lee JJ; Bedikian A; Eton O; Papadopoulos N; Plager C; Legha SS; Benjamin RS
Melanoma Res; 1998 Apr; 8(2):145-8. PubMed ID: 9610867
[TBL] [Abstract][Full Text] [Related]
11. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
12. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
[TBL] [Abstract][Full Text] [Related]
13. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.
Majer M; Jensen RL; Shrieve DC; Watson GA; Wang M; Leachman SA; Boucher KM; Samlowski WE
Cancer; 2007 Sep; 110(6):1329-37. PubMed ID: 17623835
[TBL] [Abstract][Full Text] [Related]
14. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
Tarhini AA; Kirkwood JM; Gooding WE; Cai C; Agarwala SS
J Clin Oncol; 2007 Sep; 25(25):3802-7. PubMed ID: 17761969
[TBL] [Abstract][Full Text] [Related]
15. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
Eton O; Legha SS; Bedikian AY; Lee JJ; Buzaid AC; Hodges C; Ring SE; Papadopoulos NE; Plager C; East MJ; Zhan F; Benjamin RS
J Clin Oncol; 2002 Apr; 20(8):2045-52. PubMed ID: 11956264
[TBL] [Abstract][Full Text] [Related]
16. Biochemotherapy for metastatic melanoma with limited central nervous system involvement.
Boasberg PD; O'Day SJ; Kristedja TS; Martin M; Wang H; Deck R; Shinn K; Ames P; Tamar B; Petrovich Z
Oncology; 2003; 64(4):328-35. PubMed ID: 12759528
[TBL] [Abstract][Full Text] [Related]
17. A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes.
Kounalakis N; Gao D; Gonzalez R; Becker M; Lewis K; Poust J; Pearlman N; Robinson W; McCarter M
Immunotherapy; 2012 Jul; 4(7):679-86. PubMed ID: 22853754
[TBL] [Abstract][Full Text] [Related]
18. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
González Cao M; Malvehy J; Martí R; Conill C; Sánchez M; Martín M; Carrera C; Herrero J; Gascón P; Mellado B; Castel T; Puig S
Melanoma Res; 2006 Feb; 16(1):59-64. PubMed ID: 16432457
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
20. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Kirkwood JM; Strawderman MH; Ernstoff MS; Smith TJ; Borden EC; Blum RH
J Clin Oncol; 1996 Jan; 14(1):7-17. PubMed ID: 8558223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
